TY - JOUR
T1 - The Effect of Point Mutations on the Biophysical Properties of an Antimicrobial Peptide
T2 - Development of a Screening Protocol for Peptide Stability Screening
AU - Pohl, Christin
AU - Zalar, Matja
AU - Bialy, Inas El
AU - Indrakumar, Sowmya
AU - Peters, Günther H J
AU - Friess, Wolfgang
AU - Golovanov, Alexander P
AU - Streicher, Werner W
AU - Noergaard, Allan
AU - Harris, Pernille
N1 - Funding Information:
The synchrotron SAXS data were collected at beamline P12 operated by EMBL Hamburg at the Petra II storage ring (DESY, Hamburg, Germany) and at the BioSAXS beamline, BM29, at the European Synchrotron Radiation Facility (ESRF), Grenoble, France. For local support, we thank Melissa Gräwert, Stefano Da Vela, Andrey Gruzinov, Karen Manalastas (all: EMBL, Hamburg), and Martha Brennich (ESRF, Grenoble) This work was funded by the European Union’s Horizon 2020 research and innovation program (grant agreement no. 675074). We thank the Danish Agency for Science, Technology, and Innovation for funding the instrument center DanScatt. Simulations were performed at the high-performance computing (HPC) services at DTU and in-house CPU/GPU cluster facilities at DTU chemistry. We thank Alina Kulakova for her assistance in the SAXS measurements. The first author would like to thank the whole PIPPI consortium for continuous collaboration and constructive discussions.
Publisher Copyright:
Copyright © 2020 American Chemical Society.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9/8
Y1 - 2020/9/8
N2 - Therapeutic peptides and proteins show enormous potential in the pharmaceutical market, but high costs in discovery and development are limiting factors so far. Single or multiple point mutations are commonly introduced in protein drugs to increase their binding affinity or selectivity. They can also induce adverse properties, which might be overlooked in a functional screen, such as a decreased colloidal or thermal stability, leading to problems in later stages of the development. In this study, we address the effect of point mutations on the stability of the 4.4 kDa antimicrobial peptide plectasin, as a case study. We combined a systematic high-throughput biophysical screen of the peptide thermal and colloidal stability using dynamic light scattering and differential scanning calorimetry with structure-based methods including small-angle X-ray scattering, analytical ultracentrifugation, and nuclear magnetic resonance spectroscopy. Additionally, we applied molecular dynamics simulations to link obtained protein stability parameters to the protein's molecular structure. Despite their predicted structural similarities, all four plectasin variants showed substantially different behavior in solution. We observed an increasing propensity of plectasin to aggregate at a higher pH, and the introduced mutations influenced the type of aggregation. Our strategy for systematically assessing the stability and aggregation of protein drugs is generally applicable and is of particular relevance, given the increasing number of protein drugs in development.
AB - Therapeutic peptides and proteins show enormous potential in the pharmaceutical market, but high costs in discovery and development are limiting factors so far. Single or multiple point mutations are commonly introduced in protein drugs to increase their binding affinity or selectivity. They can also induce adverse properties, which might be overlooked in a functional screen, such as a decreased colloidal or thermal stability, leading to problems in later stages of the development. In this study, we address the effect of point mutations on the stability of the 4.4 kDa antimicrobial peptide plectasin, as a case study. We combined a systematic high-throughput biophysical screen of the peptide thermal and colloidal stability using dynamic light scattering and differential scanning calorimetry with structure-based methods including small-angle X-ray scattering, analytical ultracentrifugation, and nuclear magnetic resonance spectroscopy. Additionally, we applied molecular dynamics simulations to link obtained protein stability parameters to the protein's molecular structure. Despite their predicted structural similarities, all four plectasin variants showed substantially different behavior in solution. We observed an increasing propensity of plectasin to aggregate at a higher pH, and the introduced mutations influenced the type of aggregation. Our strategy for systematically assessing the stability and aggregation of protein drugs is generally applicable and is of particular relevance, given the increasing number of protein drugs in development.
KW - aggregation assessment
KW - peptide screening
KW - pharmaceutical screening
KW - protein aggregation
KW - protein characterization
KW - protein engineering
KW - protein-protein interactions
UR - http://www.scopus.com/inward/record.url?scp=85090507119&partnerID=8YFLogxK
U2 - 10.1021/acs.molpharmaceut.0c00406
DO - 10.1021/acs.molpharmaceut.0c00406
M3 - Article
C2 - 32609526
SN - 1543-8384
VL - 17
SP - 3298
EP - 3313
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
IS - 9
ER -